1,861 reports of this reaction
2.1% of all DAPAGLIFLOZIN reports
#7 most reported adverse reaction
BLOOD GLUCOSE INCREASED is the #7 most commonly reported adverse reaction for DAPAGLIFLOZIN, manufactured by AstraZeneca Pharmaceuticals LP. There are 1,861 FDA adverse event reports linking DAPAGLIFLOZIN to BLOOD GLUCOSE INCREASED. This represents approximately 2.1% of all 89,435 adverse event reports for this drug.
Patients taking DAPAGLIFLOZIN who experience blood glucose increased should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
BLOOD GLUCOSE INCREASED is a less commonly reported adverse event for DAPAGLIFLOZIN, but still significant enough to appear in the safety profile.
In addition to blood glucose increased, the following adverse reactions have been reported for DAPAGLIFLOZIN:
The following drugs have also been linked to blood glucose increased in FDA adverse event reports:
BLOOD GLUCOSE INCREASED has been reported as an adverse event in 1,861 FDA reports for DAPAGLIFLOZIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
BLOOD GLUCOSE INCREASED accounts for approximately 2.1% of all adverse event reports for DAPAGLIFLOZIN, making it a notable side effect.
If you experience blood glucose increased while taking DAPAGLIFLOZIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.